ReAssessment of Anti-Platelet Therapy Using an InDividualized Strategy Based on GENetic Evaluation

A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 200 participants.

Also called NCT01184300

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 2/3
Enrolled
  • 200 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01184300
Other papers using this trial's data
  • Point-of-care genetic testing for personalisation of antiplatelet treatment (RAPID GENE): a prospective, randomised, proof-of-concept trial Lancet (London, England), 2012-05-05 DOI, PubMed 22464343

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Canada (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01184300. Randomized; no masking; primary purpose treatment. Start 2010-08 (registry gives no type); primary completion 2011-07 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
ReAssessment of Anti-Platelet Therapy Using an InDividualized Strategy Based on GENetic Evaluation
Acronym
RAPID GENE
Condition
Stable Coronary Artery Disease
Condition
Acute Coronary Syndrome
Intervention (Genetic)
Point-of-care genetic screening with subsequent prasugrel administration to CYP2C19*2 carriers
Lead sponsor
Ottawa Heart Institute Research Corporation (class: other)
Collaborator
Spartan Bioscience Inc. (class: industry)

Record details

Record id
cardio:ct-nct01184300
Content hash
c7cd8d24f05eb4d8736da336574cc8ddfc40d3cd2c04b0ebaa083cfa80e511eb